Company Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands.
Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma.
In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers.
The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
| Country | Netherlands |
| Founded | 2003 |
| IPO Date | May 19, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 229 |
| CEO | Dr. Sven Ante Lundberg M.D. |
Contact Details
Address: Yalelaan 62 3584 Cm Utrecht, P7 3584 CM Netherlands | |
| Phone | 31 030 253 8800 |
| Website | merus.nl |
Stock Details
| Ticker Symbol | MRUS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001651311 |
| CUSIP Number | N5749R100 |
| ISIN Number | NL0011606264 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sven Ante Lundberg M.D. | Chief Executive Officer, President and Executive Director |
| Gregory D. Perry | Chief Financial Officer |
| Peter B. Silverman J.D. | EVice President, Company Secretary, Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal |
| Dr. Hui Liu Ph.D. | Chief Business Officer, Executive Vice President and Head of Merus U.S. |
| Dr. Andrew Joe M.D. | Chief Medical Officer and Senior Vice President |
| Dr. Hennie Hoogenboom | Co-Founder and Scientific Advisor |
| Harry Shuman | Chief Accounting Officer |
| Cornelis Adriaan de Kruif Ph.D. | Chief Technology Officer and Executive Vice President |
| Dr. Cecilia Anna Wilhelmina Geuijen Ph.D. | Chief Scientific Officer and Senior Vice President |
| Kathleen Farren | IR and Corporate Communications Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 10, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 29, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 25, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 6, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Mar 6, 2024 | 8-K | Current Report |
| Feb 28, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 28, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Feb 28, 2024 | 10-K | Annual Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |